According to filings with the U.S. Securities and Exchange Commission, 410 Medical is raising up to $12 Million in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About 410 Medical
410 Medical is a North Carolina-based medical device company focused on developing innovative technologies that help save the lives of critically ill patients by improving resuscitation. The companys mission is to provide advanced tools that assist healthcare providers in delivering rapid, effective volume resuscitation, supported by education for clinicians and policy makers on the importance of timely fluid delivery in emergency and critical care. Its flagship product line, LifeFlow rapid infusers, is designed to enhance the speed and efficiency of administering fluids and blood products for patients with life-threatening conditions such as sepsis, hemorrhagic shock, and other forms of critical illness, and these products are designed, engineered, and assembled in the USA. 410 Medical takes its name from pediatric septic shock fluid delivery goals in ACCM/PALS guidelines, reflecting its clinical focus on meeting demanding resuscitation targets in real-world practice. Founded in 2013, the company positions itself as a compassionate, intelligent, science- and outcome-driven partner to healthcare teams, and has secured significant Series B financing to expand access to its life-saving resuscitation technologies.

To learn more, visit https://www.410medical.com/
LinkedIn: https://www.linkedin.com/company/410-medical

Contact:
Kyle Chenet, Chief Executive Officer

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.